William Blair Weighs in on TransMedics Group, Inc.’s Q3 2024 Earnings (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDX) – William Blair lifted their Q3 2024 EPS estimates for TransMedics Group in a research report issued on Wednesday, July 31st. William Blair analyst R. Daniels now anticipates that the company will earn $0.03 per share for the quarter, up from their previous forecast of $0.02. The consensus estimate for TransMedics Group’s current full-year earnings is $0.82 per share.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Wednesday, July 31st. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.14. TransMedics Group had a net margin of 0.84% and a return on equity of 17.37%. The firm had revenue of $114.30 million for the quarter, compared to the consensus estimate of $98.84 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. The company’s revenue for the quarter was up 117.7% compared to the same quarter last year.

Other equities research analysts have also recently issued research reports about the stock. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, June 7th. Piper Sandler raised their price objective on shares of TransMedics Group from $170.00 to $180.00 and gave the stock an “overweight” rating in a research note on Thursday. Oppenheimer increased their target price on TransMedics Group from $125.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday. JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research report on Wednesday, May 1st. Finally, Canaccord Genuity Group increased their target price on TransMedics Group from $117.00 to $169.00 and gave the company a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $166.88.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $150.10 on Friday. TransMedics Group has a twelve month low of $36.42 and a twelve month high of $171.98. The company’s 50 day moving average is $144.02 and its 200 day moving average is $111.28. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The company has a market cap of $4.94 billion, a PE ratio of -441.47 and a beta of 1.99.

Hedge Funds Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its stake in TransMedics Group by 1.7% during the third quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after purchasing an additional 29,798 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in TransMedics Group by 10.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 397,283 shares of the company’s stock worth $31,358,000 after purchasing an additional 38,951 shares during the last quarter. Moody Aldrich Partners LLC lifted its stake in TransMedics Group by 110.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after purchasing an additional 24,290 shares during the last quarter. Alpha DNA Investment Management LLC purchased a new stake in TransMedics Group during the fourth quarter worth approximately $500,000. Finally, Russell Investments Group Ltd. lifted its stake in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock worth $1,997,000 after purchasing an additional 26,997 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Insider Buying and Selling

In related news, Director David Weill sold 1,193 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total transaction of $168,988.45. Following the completion of the sale, the director now directly owns 10,732 shares of the company’s stock, valued at approximately $1,520,187.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other TransMedics Group news, Director David Weill sold 1,193 shares of TransMedics Group stock in a transaction dated Wednesday, May 29th. The stock was sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the transaction, the director now directly owns 10,732 shares of the company’s stock, valued at approximately $1,520,187.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Waleed H. Hassanein sold 30,000 shares of TransMedics Group stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $130.07, for a total value of $3,902,100.00. Following the completion of the transaction, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,017,905.01. The disclosure for this sale can be found here. In the last ninety days, insiders sold 101,342 shares of company stock valued at $13,642,015. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.